T1	Participants 50 148	advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials
T2	Participants 255 368	advanced or recurrent endometrial cancer patients participating in Gynecologic Oncology Group chemotherapy trials
T3	Participants 912 965	1203 patients treated on 4 randomized clinical trials
